Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 4, 2001, Pages 1504-1510

  Backeljauw, Philippe F ^b   Underwood, Louis E ^a   Miras, M ^c   Arriazu, M C ^c   Heinrich, J ^c   Ghizzoni, L ^c   Blethen, S ^d   Donaldson, D ^c   Cleveland, W ^c   Duncan, V ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c Children's Hospital Medical Center ^*

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ARTICLE; BODY FAT; BODY WEIGHT; BONE AGE; CLINICAL ARTICLE; CLINICAL FEATURE; GROWTH HORMONE BLOOD LEVEL; HEIGHT; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; HYPOGLYCEMIA; KIDNEY; LARON SYNDROME; LONG TERM CARE; PRIORITY JOURNAL; SCHOOL CHILD; SHORT STATURE; SPLEEN; TREATMENT INDICATION; VELOCITY;

BODY COMPOSITION; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DRUG RESISTANCE; FACIES; FEMALE; HEART; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY; LYMPHOID TISSUE; MALE; RECOMBINANT PROTEINS; SPLEEN; SYNDROME;

EID: 17744390350     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.4.1504     Document Type: Article

References (39)

1. Growth hormone (GH) insensitivity due to primary GH receptor deficiency
2. Growth hormone insensitivity
3. Laron syndrome: Primary growth hormone resistance
4. Growth hormone receptor deficiency in Ecuador
5. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome)
6. The somatomedins: Biological actions and physiological control mechanisms
7. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome
8. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients with Laron-type dwarfism
9. Therapeutic response to recombinant IGF-I on thirty-two patients with growth hormone insensitivity
10. A randomized, double-blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency
11. Three year IGF-I treatment of children with Laron syndrome
12. Insulin-like growth factor I improves height in growth hormone insensitivity: Two years' results
13. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome-A Clinical Research Center Study
14. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome
15. Long-term treatment of growth hormone insensitivity syndrome with IGF-I-Results of the European Multicentre Study
16. Two-year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: Comparison of two dosage levels and to GH-treated GH deficiency
17. Five-year treatment with IGF-I of a patient with Laron syndrome in Slovenia (a follow-up report)
18. Weight/height compared to weight/height 53 for assessing adiposity in childhood: Influence of age during puberty
19. Induction of immunoreactive somatomedin C in human serum by growth hormone: Dose-response relationships and effect on chromatographic profiles
20. Serum concentrations of insulin-like growth factor II are not changed by short term fasting and refeeding
21. Effects of 4-years treatment with recombinant human insulin-like growth factor-I (rhIGF-I) on craniofacial growth in children with growth hormone insensitivity syndrome (GHIS)
22. A dual effector theory of growth hormone action
23. Serum levels of insulin-like growth factor binding proteins in Ecuadorian children with growth hormone insensitivity
24. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
25. Normal growth and development in the absence of hepatic insulin-like growth factor-I
26. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex
27. Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: Further evidence for the action of insulin-like growth factors through the insulin receptor
28. Recombinant human insulin-like growth factor-I stimulates growth and has distinct effects on organ size in hypophysectomized rats
29. Clinical and biochemical characteristics of growth hormone receptor deficiency (Laron syndrome)
30. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome
31. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance)
32. Growth hormone increases rate of pubertal maturation
33. Sex steroids, growth hormone, insulin-like growth factor-I: Neuroendocrine and metabolic regulation in puberty
34. Insulin-like growth factor-I as an amplifier of follicle-stimulating hormone action: Studies on mechanism(s) and site(s) of action in cultured rat granulosa cells
35. Physical growth: National Center for Health Statistics percentiles
36. Measurement of bone mineral content of the lumbar spine by dual-energy x-ray absorptiometry in normal children: Correlations with growth parameters
37. Normal splenic size in infants and children; sonographic measurements
38. Sonographic measurements and appearance of normal kidneys in children